Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features.

BACKGROUND AND OBJECTIVE: Topiramate has been approved by the US Food and Drug Administration for the treatment of epilepsy since the 1990s, and it has also been used off-label in the treatment of many types of addictive disorders. To date, no systematic review has embraced the entire field of addiction, both substance use and behavioral addictions, including eating disorders, to compare topiramate-based protocols and the related level of evidence in each addictive disorder. Our objective is to fill this gap. METHODS: A systematic search was conducted using the MEDLINE, PsycINFO, and Cochrane databases without a date or language limit. All trials and meta-analyses assessing the efficacy of topiramate in alcohol use disorder; cocaine use disorder; methamphetamine, nicotine, cannabis, opiate, and benzodiazepine use disorders; binge eating disorder; bulimia; and pathological gambling were analyzed. The quality of the studies was rated using the Cochrane Risk-of-Bias tool for randomized trials (ROB-2), the Risk of Bias In Nonrandomized Studies (ROBINS-I), or the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist, depending on the study design. Safety features were assessed based on a wider non-systematic review. RESULTS: Sixty-two articles were reviewed. Treatment protocols were relatively homogenous across addictive disorders, with slow dose titration schemes and a maximum dose range of 200-400 mg per day. The most supportive evidence for topiramate efficacy was found in alcohol use disorder for drinking reduction parameters only. To a lesser extent, topiramate could be a promising therapeutic option for binge eating disorder and cocaine use disorder. Evidence was weak for other addictive disorders. No major tolerability issues were found, provided that basic safety rules were followed. Adverse drug reactions could lead to early treatment discontinuation. DISCUSSION: Though off-label, addiction specialists should consider topiramate as a second-line option for drinking reduction in alcohol use disorder, as well as for binge eating disorder or cocaine use disorder.

How did I get so late so soon? A review of time processing and management in autism.

While the definition of Autism Spectrum Disorder (ASD) does not include any explicit criteria concerning difficulties of time perception or management, there is growing evidence of atypical temporal perception in individuals with ASD. This review synthesizes the evidence and gaps of the current literature on time processing in ASD. After a brief overview of clinical findings and available assessment tools, we synthetize outcomes of studies evaluating time perception at second and infra-second level, and then, recent literature on the circadian timing system. Findings point that all levels of time processing are atypical in autism (i.e. millisecond, interval and circadian timing). We discuss how time perception abnormalities and ASD core symptoms might intertwine and offer a new perspective for future research on this topic. We advocate the need to systematically assess temporal perception in ASD, and to include these aspects in global functional assessments before intervention. Implementing early intervention techniques to remediate time perception alterations in children with ASD may substantially improve their developmental trajectory.